Back to search

Peptide record

TPDB64195

Angiopep-2 Angiopep-2 (AP2) Blood-Brain Barrier Cell-penetrating Peptides standard
19 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB64195
Angiopep-2 Angiopep-2 (AP2)
Blood-Brain Barrier Cell-penetrating Peptides
Delivery and barrier-penetrating peptides
B3Pred BBPpredict Peptipedia CPPsite3.0
standard
No
A 19-aa standard natural multi-activity (Blood-Brain Barrier and Cell-penetrating Peptides) peptide sequence curated from B3Pred, BBPpredict, Peptipedia, and other sources, with an available 3D structural model.
Sequence
TFFYGGSRGKRNNFKTEEY
Physicochemical Analysis
C104H149N29O31
ADCQHILMPWV
GF
2301.50
9.97
4
2
5
+2
3.65
-1.495
0.00
Mammalian: 7.2 hour Yeast: >20 hour E.coli: >10 hour
2980
129.48
7
Residue Composition
number
0
A
2
R
2
N
0
D
0
C
2
E
0
Q
3
G
0
H
0
I
0
L
2
K
0
M
3
F
0
P
1
S
2
T
0
W
2
Y
0
V
Amino Acid Distribution
A: 0 R: 2 N: 2 D: 0 C: 0 E: 2 Q: 0 G: 3 H: 0 I: 0 L: 0 K: 2 M: 0 F: 3 P: 0 S: 1 T: 2 W: 0 Y: 2 V: 0
Chemical Descriptors
19
C104H149N29O31
2301.50
9.97
+2
3.65
-1.495
Free
L
Linear
Linear
Free
Similarity
ThrPhePheTyrGlyGlySerArgGlyLysArgAsnAsnPheLysThrGluGluTyr Thr-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-Lys-Arg-Asn-Asn-Phe-Lys-Thr-Glu-Glu-Tyr
bEnd.3 N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)O NCC(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O
Evidence Records 17 records
Evidence 1 Activity

Activity

Blood-Brain Barrier

Assay & Model

mouse
Origin/Source

Source & Reference

NA
B3Pdb
Evidence 2 Activity

Activity

Blood-Brain Barrier
15.47%

Assay & Model

Capillary depletion
Origin/Source
% capillary

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Saturable
Direct iodination
Evidence 3 Activity

Activity

Blood-Brain Barrier
84.53%

Assay & Model

Capillary depletion
Origin/Source
% parenchyma

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Saturable
Direct iodination
Evidence 4 Activity

Activity

Blood-Brain Barrier
84%

Assay & Model

Capillary depletion
Origin/Source
% parenchyma

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Saturable
Direct iodination
Evidence 5 Activity

Activity

Blood-Brain Barrier
15.63%

Assay & Model

Capillary depletion
Origin/Source
% capillary

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Saturable
Direct iodination
Evidence 6 Activity

Activity

Blood-Brain Barrier
84.37%

Assay & Model

Capillary depletion
Origin/Source
% parenchyma

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Saturable
Direct iodination
Evidence 7 Activity

Activity

Blood-Brain Barrier
16%

Assay & Model

Capillary depletion
Origin/Source
% capillary

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Saturable
Direct iodination
Evidence 8 Activity

Activity

Blood-Brain Barrier
0.04 ml/g

Assay & Model

Capillary deplition in situ b p
Origin/Source
CD(capillary/perfusate)

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Saturable
Direct iodination
Evidence 9 Activity

Activity

Blood-Brain Barrier
0.24 ml/g

Assay & Model

Capillary deplition in situ b p
Origin/Source
CD(brain/perfusate)

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Saturable
Direct iodination
Evidence 10 Activity

Activity

Blood-Brain Barrier
0.1976 ml/g

Assay & Model

Capillary deplition in situ b p
Origin/Source
CD(parenchyma/perfusate)

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Saturable
Direct iodination
Evidence 11 Activity

Activity

Blood-Brain Barrier
0.2342 ml/g

Assay & Model

Capillary deplition in situ b p
Origin/Source
CD(brain/perfusate)

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Saturable
Direct iodination
Evidence 12 Activity

Activity

Blood-Brain Barrier
0.2 ml/g

Assay & Model

Capillary deplition in situ b p
Origin/Source
CD(parenchyma/perfusate)

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Saturable
Direct iodination
Evidence 13 Activity

Activity

Blood-Brain Barrier
0.0366 ml/g

Assay & Model

Capillary deplition in situ b p
Origin/Source
CD(capillary/perfusate)

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Saturable
Direct iodination
Evidence 14 Activity

Activity

Blood-Brain Barrier
0.2317 ml/g

Assay & Model

Capillary deplition in situ b p
Origin/Source
CD(brain/perfusate)

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Saturable
Direct iodination
Evidence 15 Activity

Activity

Blood-Brain Barrier
0.2 ml/g

Assay & Model

Capillary deplition in situ b p
Origin/Source
CD(parenchyma/perfusate)

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Saturable
Direct iodination
Evidence 16 Activity

Activity

Cell-penetrating Peptides

Target

Becs, Hmvec And HUVEC Models

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L
FAM-conjugated
Angiopep-2 showed little uptake in the case of the hMVEC and HUVEC models, whereas the bEC model showed significantly high uptake of the CPPs.
LRP1-Mediated Transcytosis
In vitro
CCHHHHTTCC
Evidence 17 Activity

Activity

Cell-penetrating Peptides

Target

Shsy-5Y Cells

Assay & Model

C57BL/6 mice
C57BL/6 mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Protein derived
PAPTP-Linker (PAPTPL)
An2-PAPTP could reach the brain and did not show toxicity, in contrast to TAT-PAPTP.
In vitro and in vivo
CCCCCCSCCCCSCC
Additional Detail Fields 1 fields
CCHHHHTTCC CCCCCCSCCCCSCC